Exploring the Clinical Effect of Recombinant Human Brain Natriuretic Peptide in Treating Patients with Acute Exacerbation of Chronic Heart Failure
Objective To analyze the clinical effect of recombinant human brain natriuretic peptide treatment in pa-tients with acute exacerbation of chronic heart failure.Methods 60 patients with acute exacerbation of chronic heart failure admitted to the cardiology Department of Linyi Central Hospital from June 2020 to June 2021 were randomly selected as the study objects.According to the block randomized method,the patients were divided into control group and study group,with 30 cases in each group.The patients in the control group received conventional treatment,and the patients in the study group received conventional treatment plus recombinant human brain natriuretic peptide therapy.The therapeutic value of recombinant human brain natriuretic peptide was analyzed.Results After treatment,erythrocyte sedimentation rate,hematocrit,plasma dynamic viscosity,whole blood dynamic viscosity,blood plasma dy-namic viscosity,QT interval dispersion level,left anterior descending coronary artery diameter,left ventricular end-diastolic diameter and left ventricular end-systolic diameter were lower in the study group,and left ventricular ejec-tion fraction was higher,the differences were statistically significant(all P<0.05).After treatment,the levels of serum creatinine(77.31±6.43)µmol/L,brain natriuretic peptide precursor(1 328.43±150.96)pg/mL were lower in the study group,and the levels of epidermal growth factor receptor(55.31±5.29)mL/(min·1.73 m2)were higher,the differences were statistically significant(t=6.243,5.228,6.351,all P<0.05).Conclusion Recombinant human brain natriuretic peptide treatment was more superior in improving patients'heart failure-related indexes,cardiac function and blood flow rheology indexes,and patients had better clinical outcomes after treatment.
Acute exacerbation of chronic heart failureRecombinant human brain natriuretic peptideCardiac function
万方数据
维普
